Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Cutaneous adverse events: a predictor of tumor response under anti-PD-1 therapy for metastatic melanoma, a cohort analysis of 189 patients.

< BACK TO ARCHIVE


2020 Feb 20


J Eur Acad Dermatol Venereol


http://www.ncbi.nlm.nih.gov/pubmed/32078191?dopt=Abstract

Cutaneous adverse events: a predictor of tumor response under anti-PD-1 therapy for metastatic melanoma, a cohort analysis of 189 patients.

Authors

Cutaneous adverse events: a predictor of tumor response under anti-PD-1 therapy for metastatic melanoma, a cohort analysis of 189 patients.
Bottlaender L, Amini-Adle M, Maucort-Boulch D, Robinson P, Thomas L, Dalle S
J Eur Acad Dermatol Venereol. 2020 Feb 20.
PMID: 32078191.

Abstract

Cutaneous adverse events (AE) are the most prevalent toxicity under checkpoint-inhibitors in clinical trials. In "real-life" conditions of use, skin toxicities under anti-PD-1 have not been described to date in a large cohort. The objective of this study was to determine the clinical features of skin toxicities in patients with advanced melanoma receiving anti-PD-1 therapy under "real-life"-conditions of use. Secondary objectives were to evaluate the characteristics of patients with skin toxicities and to analyze associated extra-cutaneous toxicities, progression-free-survival (PFS) and overall-survival (OS).
Read This Paper